PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics to Present at Upcoming Healthcare Investor Conferences
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 9, 2017-- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2017 HEALTHCARE CONFERENCE When: November 14, 2017 at 8:00
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and Third Quarter 2017 Results
Ongoing discussions with U.S. Food and Drug Administration ( FDA ) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation in mid-2018 Pro forma cash balance of $132.1 million as of September 30 Two abstracts accepted as oral presentations at the 2017 American Society of
View HTML
Toggle Summary GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017
ROCKVILLE, Md ,--(BUSINESS WIRE)--Nov. 1, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting
GMI-1271 improves efficacy and safety of chemotherapy in Phase 1/2 study in two acute myeloid leukemia (AML) patient populations Preclinical data detail underlying mechanism for GMI-1271’s ability to enhance sensitivity to chemotherapy GlycoMimetics will review the GMI-1271 clinical data during a
View HTML
Toggle Summary GlycoMimetics to Present at Biocentury's Newsmakers in the Biotech Industry Conference
ROCKVILLE, MD --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will present at BioCentury's Newsmakers in the Biotech Industry Conference. The presentation will take place on Friday, September 8, 2017 at 1:30 p.m.
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and Second Quarter 2017 Results
FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML) Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML Clinicians
View HTML
Toggle Summary GlycoMimetics to Receive European Patent for GMI-1271
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use." This
View HTML
Toggle Summary GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
ROCKVILLE, Md. --(BUSINESS WIRE)--Jun. 12, 2017-- GlycoMimetics , Inc. (NASDAQ:GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc. , to its Board of Directors. “It’s an asset to our Board and GlycoMimetics as a whole to be
View HTML
Toggle Summary GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2017 Global Healthcare Conference in New York City , on Wednesday, June 7, 2017 , at 2:00 p.m. ET .
View HTML
Toggle Summary GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting
Remission rates continue to be higher than historical controls and induction-related mortality continues to be lower than historical controls GMI-1271 continues to be well tolerated in combination with induction chemotherapy Only one case of severe (Grade 3/4) mucositis reported among 79 patients
View HTML